Peyravian et al. reported high mRNA levels of CD86 in adenomatous polyps, and thus suggested the utilization of this biomarker as a means to distinguish them from hyperplastic polyps, hinting at the potential role of CD86 in malignant transformation [77]. This evidence concerns the gene CD86 and hyperplastic polyp.